Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016
November 15, 2016 at 03:30 am IST
Share
Arno Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company reported loss from operations of $2,232,000 compared to $2,875,000 a year ago. Net loss was $3,849,000 or loss of $0.09 per diluted share compared to net loss of $679,000 or $0.03 per diluted share a year ago. Non-GAAP adjusted net loss was $813,000 or loss of $0.02 per basic share compared to $1,945,000 or $0.10 per basic share a year ago.
For the nine months, the company reported loss from operations of $8,367,000 compared to $10,716,000 a year ago. Net loss was $9,700,000 or loss of $0.23 per diluted share compared to $7,513,000 or $0.37 per diluted share a year ago. Non-GAAP adjusted net loss was $4,962,000 or loss of $0.12 per basic share compared to $7,842,000 or $0.38 per basic share a year ago.
Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.
ARNO THERAPEUTICS, INC. 
